Boston Scientific Corp (BSX)vsCONMED Corporation (CNMD)
BSX
Boston Scientific Corp
$48.55
-0.34%
HEALTHCARE · Cap: $70.87B
CNMD
CONMED Corporation
$35.16
+0.09%
HEALTHCARE · Cap: $1.05B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 1404% more annual revenue ($20.61B vs $1.37B). BSX leads profitability with a 17.3% profit margin vs 4.0%. BSX appears more attractively valued with a PEG of 0.58. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
CNMD
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.4%
Fair Value
$37.35
Current Price
$48.55
$11.20 premium
Margin of Safety
+27.9%
Fair Value
$58.71
Current Price
$35.16
$23.55 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Reasonable price relative to book value
Earnings expanding 136.8% YoY
Areas to Watch
No major concerns identified
Expensive relative to growth rate
Grey zone — moderate risk
Smaller company, higher risk/reward
ROE of 5.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : CNMD
The strongest argument for CNMD centers on Price/Book, EPS Growth.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : CNMD
The primary concerns for CNMD are PEG Ratio, Altman Z-Score, Market Cap. Thin 4.0% margins leave little buffer for downturns.
Key Dynamics to Monitor
BSX profiles as a mature stock while CNMD is a value play — different risk/reward profiles.
CNMD carries more volatility with a beta of 0.92 — expect wider price swings.
BSX is growing revenue faster at 11.6% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 59/100), backed by strong 17.3% margins and 11.6% revenue growth. CNMD offers better value entry with a 27.9% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
CONMED Corporation
HEALTHCARE · MEDICAL DEVICES · USA
CONMED Corporation, a medical technology company, develops, manufactures and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company is headquartered in Largo, Florida.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?